1 study found for:    ((BAY86-9766 AND GIST) OR NCT01392521)
Show Display Options
Rank Status Study
1 Active, not recruiting Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
Condition: Neoplasms
Intervention: Drug: Copanlisib + Refametinib (BAY86-9766)

Indicates status has not been verified in more than two years